John W Smither
CIK 1559583 · Chief Financial Officer · last filed 2026-07-02
John W Smither is a Chief Financial Officer who has filed 78 SEC Form 4 insider transactions across 9 companies since 2013. The most recent filing shows the insider sold $34.9K of GNLX on Jul 2, 2026. Across all open-market trades the lifetime net is −$8.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$4.57M
9
78
-$8.67M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GNLX | Director | 91,403 | $2.92 | $266.9K | -$53.6K | 8 | 2026-07-02 |
| NAMSW | Director | 10,360 | $19.38 | $200.8K | $0 | 3 | 2026-01-09 |
| ARQT | Chief Financial Officer | 144,185 | $28.42 | $4.10M | -$619.5K | 12 | 2024-02-15 |
| Applied Molecular Transport Inc. (AMTI) Delisted | Director | — | $0.26 | — | $0 | 4 | 2023-12-28 |
| eFFECTOR Therapeutics, Inc. (EFTRW) Delisted | Director | 24,142 | $0.00 | $14 | $0 | 5 | 2023-06-22 |
| Principia Biopharma Inc. (PRNB) Delisted | Director | — | — | — | $0 | 1 | 2019-02-21 |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | Chief Financial Officer | 81,618 | — | — | $0 | 3 | 2019-01-03 |
| Achaogen, Inc. (AKAO) Delisted | Director | — | — | — | $0 | 5 | 2018-06-07 |
| KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | Chief Financial Officer | 0 | — | — | -$7.99M | 34 | 2015-10-02 |
Recent Filings
78 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | GNLX | Sell (S) | −12,000 | -$34.9K | EDGAR |
| 2026-07-01 | GNLX | Notice (144) | −12,000 | -$34.9K | EDGAR |
| 2026-06-18 | GNLX | Grant (A) | +28,409 | $0 | EDGAR |
| 2026-01-09 | NAMSW | Grant (A) | +3,400 | $0 | EDGAR |
| 2025-08-29 | GNLX | Grant (A) | +22,283 | $0 | EDGAR |
| 2025-01-08 | NAMSW | Grant (A) | +6,960 | $0 | EDGAR |
| 2024-12-31 | GNLX | Grant (A) | — | $0 | EDGAR |
| 2024-08-05 | GNLX | Grant (A) | +39,541 | $0 | EDGAR |
| 2024-06-26 | ARQT | Notice (144) | −7,396 | -$68.5K | EDGAR |
| 2024-06-07 | GNLX | Buy (P) | +6,250 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.